November 14, 2019
The Special Committee of the Board of Directors of Intrexon Corporation (NASDAQ: XON), a publicly traded biopharmaceutical and bioengineering company, engaged Cascadia Capital to provide a fairness opinion for its divestiture of a stake in AquaBounty Technologies, LLC (NASDAQ: AQB), a genetically-modified salmon producer.
Founded in 1991, AquaBounty Technologies is an aquaculture company that uses a proprietary gene technology to radically improve land-based farming of Atlantic salmon. The resulting faster growth and greater feed efficiency mean a more efficient use of capital, reduced feed costs and less time to market when compared to the Company’s competitors.
The fairness opinion provided Intrexon with thorough valuation guidance and an unbiased, defensible third-party perspective.
As an independent investment bank, Cascadia Capital delivers high-quality, conflict-free financial advice and opinions to boards and special committees that withstand the most rigorous scrutiny. Past fairness opinions include: Boyne Resorts, Intellectual Ventures, Helix Biomedix, R.W. Beck, CostULess, and Imperium Renewables
For more information about this engagement, please contact the Cascadia Capital deal team:
CEO & Managing Director
Senior Vice President